Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment

Cancer Discovery

Volumn 3, Issue 12, 2013, Pages 1330-1332

  Rech, Andrew J ^a   Vonderheide, Robert H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER SPECIFIC SURVIVAL; CYTOLOGY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KRAS MUTATION; LUNG NON SMALL CELL CANCER; ONCOGENE; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84890018322     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0775     Document Type: Article

References (11)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
4. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
5. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3: 1355-63.
6. Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Gröne A, Sibilia M, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 2013; 38: 275-84.
7. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007; 104: 19055-60.
8. Imielinski MM, Berger AHA, Hammerman PSP, Hernandez BB, Pugh TJT, Hodis EE, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
9. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369: 187-9.
10. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8 T cells. Sci Transl Med 2013; 5: 200ra116.
11. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger B Z, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21: 822-35.